Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma

Journal of Pathology

Volumn 225, Issue 1, 2011, Pages 83-95

  Hurbin, Amandine ^a,b   Wislez, Marie ^c,d,e   Busser, Benoît ^a,b,f   Antoine, Martine ^c,d,e   Tenaud, Corine ^a,b,f   Rabbe, Nathalie ^c,d   Dufort, Sandrine ^a,b,f   De Fraipont, Florence ^a,b,f   Moro Sibilot, Denis ^a,b,e,f   Cadranel, Jacques ^c,d,e   Coll, Jean Luc ^a,b   Brambilla, Elisabeth ^a,b,e,f  

^a INSTITUT ALBERT BONNIOT   (France)

^b UNIV GRENOBLE ALPES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL TENON   (France)

^e Intergroupe Francophone de Cancérologie Thoracique IFCT   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

amphiregulin; EGFR TKI; IGF1R; lung adenocarcinoma; mucinous

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; MUCINOUS CARCINOMA; ONCOGENE K RAS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 79960337010     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2897     Document Type: Article

References (44)

1. Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al., Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132. (Pubitemid 41058344)
3. Motoi N, Szoke J, Riely GJ, et al., Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-827.
4. Fukuoka M, Yano S, Giaccone G, et al., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237-2246. (Pubitemid 46621858)
5. Kris MG, Natale RB, Herbst RS, et al., Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 2003; 290: 2149-2158. (Pubitemid 37432975)
6. Miller VA, Kris MG, Shah N, et al., Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103-1109. (Pubitemid 41095044)
7. Hirsch FR, Varella-Garcia M, McCoy J, et al., Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005; 23: 6838-6845.
8. Cadranel J, Quoix E, Baudrin L, et al., IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. J Thorac Oncol 2009; 4: 1126-1135.
9. Travis WD, Brambilla E, Muller-Hermelink HK, et al., Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon, 2004.
10. Travis WD, Brambilla E, Noguchi M, et al., IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
11. Wislez M, Antoine M, Baudrin L, et al., Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer 2009; 68: 185-191.
12. Finberg KE, Sequist LV, Joshi VA, et al., Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007; 9: 320-326. (Pubitemid 47305068)
13. Hata A, Katakami N, Fujita S, et al., Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol 2010; 5: 1197-1200.
14. Massarelli E, Varella-Garcia M, Tang X, et al., KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007; 13: 2890-2896. (Pubitemid 46849563)
15. Ishikawa N, Daigo Y, Takano A, et al., Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005; 65: 9176-9184. (Pubitemid 41507981)
16. Busser B, Sancey L, Josserand V, et al., Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers. Mol Ther 2010; 18: 528-535.
17. Morgillo F, Woo JK, Kim ES, et al., Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66: 10100-10111. (Pubitemid 44672064)
18. Knowlden JM, Jones HE, Barrow D, et al., Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat 2008; 111: 79-91. (Pubitemid 352009232)
19. Guix M, Faber AC, Wang SE, et al., Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609-2619. (Pubitemid 351949788)
20. Beasley MB, Brambilla E, Travis WD,. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005; 40: 90-97. (Pubitemid 40417889)
21. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. (Pubitemid 38637993)
22. Hurbin A, Coll JL, Dubrez-Daloz L, et al., Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax- and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells. J Biol Chem 2005; 280: 19757-19767. (Pubitemid 41379501)
23. Dziadziuszko R, Merrick DT, Witta SE, et al., Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010; 28: 2174-2180.
24. Selvaggi G, Novello S, Torri V, et al., Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004; 15: 28-32. (Pubitemid 38139599)
25. Cappuzzo F, Toschi L, Tallini G, et al., Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2006; 17: 1120-1127. (Pubitemid 43985248)
26. Hurbin A, Dubrez L, Coll JL, et al., Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor dependent pathway in non-small cell lung cancer cell lines. J Biol Chem 2002; 277: 49127-49133. (Pubitemid 36014341)
27. Tanaka H, Yanagisawa K, Shinjo K, et al., Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007; 67: 6007-6011. (Pubitemid 47037477)
28. Shigematsu H, Gazdar AF,. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118: 257-262. (Pubitemid 41779062)
29. Addison CL, Ding K, Zhao H, et al., Plasma transforming growth factor α and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol 2010; 28: 5247-5256.
30. Ludovini V, Bellezza G, Pistola L, et al., High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 2009; 20: 842-849.
31. Eckstein N, Servan K, Girard L, et al., Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 2008; 283: 739-750.
32. Wang X, Masri S, Phung S, et al., The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. Cancer Res 2008; 68: 2259-2265. (Pubitemid 351521799)
33. Khambata-Ford S, Garrett CR, Meropol NJ, et al., Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237. (Pubitemid 47325606)
34. Yamada M, Ichikawa Y, Yamagishi S, et al., Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer Res 2008; 14: 2351-2356. (Pubitemid 351551067)
35. Yonesaka K, Zejnullahu K, Lindeman N, et al., Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 2008; 14: 6963-6973.
36. Chakravarti A, Loeffler JS, Dyson NJ,. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62: 200-207. (Pubitemid 34074005)
37. Jones HE, Goddard L, Gee JM, et al., Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11: 793-814. (Pubitemid 40065552)
38. Nahta R, Yuan LX, Zhang B, et al., Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65: 11118-11128. (Pubitemid 41713383)
39. Pollak M,. Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev Cancer 2008; 8: 915-928.
40. Karp DD, Paz-Ares LG, Novello S, et al., Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009; 27: 2516-2522.
41. Jassem J, Langer CJ, Karp DD, et al., Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). 2010 ASCO Annual Meeting 2010. J Clin Oncol 2010; 28: (Suppl): 7500 (Abstract).
42. Yotsumoto F, Fukami T, Yagi H, et al., Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci 2010; 101: 2351-2360.
43. Liu B, Fang M, Lu Y, et al., Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 2001; 20: 1913-1922. (Pubitemid 32458701)
44. Memmott RM, Mercado JR, Maier CR, et al., Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Philadelphia) 2010; 3: 1066-1076.